Nesfatin-1 crosses the blood-brain barrier (BBB) without saturation, which could be of clinical significance for its use as a pharmacological agent for obesity treatment (Pan et al., 2007; Price et al., 2007). This evidence concerns the gene NUCB2 and obesity disorder.